##common.pageHeaderLogo.altText##

Review article: Medical guidelines

Vol. 155 No. 7 (2025)

Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network

Cite this as:
Swiss Med Wkly. 2025;155:4219
Published
17.07.2025

Summary

Since the publication of the first Swiss recommendations on systemic light-chain amyloidosis in 2020, treatment strategies have evolved. As a result of the third joint meeting of the Swiss Amyloidosis Network, a multidisciplinary and multicentre Swiss clinical consortium, in 2024, recommendations for the treatment of light-chain amyloidosis were updated. They discuss the role of the new standard first-line protocol Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone (Dara-CyBorD), the timing and indication of high-dose treatment and potential second-line strategies as well as emerging treatment options, with a special focus on multidisciplinary supportive care measures. The update represents a synopsis of current evidence and expert consensus and intends to provide general treatment guidance tailored to the Swiss healthcare system. Nonetheless, treatment decisions should always be personalised and involve a multidisciplinary approach. This update replaces the previous “therapeutic recommendations” while the previous “diagnostic recommendations” remain valid.

References

  1. Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, et al. Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. Swiss Med Wkly. 2020 Dec;150(4950):w20364. doi: https://doi.org/10.4414/smw.2020.20364
  2. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008 Apr;336(7650):924–6. doi: https://doi.org/10.1136/bmj.39489.470347.AD
  3. Cluzeau F, et al.; AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care. 2003 Feb;12(1):18–23. doi: https://doi.org/10.1136/qhc.12.1.18
  4. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004 Sep;22(18):3751–7. doi: https://doi.org/10.1200/JCO.2004.03.029
  5. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013 Apr;121(17):3420–7. doi: https://doi.org/10.1182/blood-2012-12-473066
  6. Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014 Oct;124(15):2325–32. doi: https://doi.org/10.1182/blood-2014-04-570010
  7. Schönland SO, Dreger P, De Witte T, Hegenbart U. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone Marrow Transplantat. 2012;47(7:895–905. doi: https://doi.org/10.1038/bmt.2011.152
  8. Sanchorawala V. Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis. HemaSphere. 2022 Jan;6(2):e681. 10.1097/HS9.0000000000000681
  9. Sidana S, Larson DP, Greipp PT, He R, McPhail ED, Dispenzieri A, et al. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia. 2020 May;34(5):1373–82. doi: https://doi.org/10.1038/s41375-019-0667-6
  10. Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018 Oct;32(10):2240–9. doi: https://doi.org/10.1038/s41375-018-0060-x
  11. Palladini G, Merlini G. How I treat AL amyloidosis. Blood. 2022 May;139(19):2918–30. doi: https://doi.org/10.1182/blood.2020008737
  12. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012 Dec;30(36):4541–9. doi: https://doi.org/10.1200/JCO.2011.37.7614
  13. Palladini G, Paiva B, Wechalekar A, Massa M, Milani P, Lasa M, et al. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer J. 2021 Feb;11(2):34. doi: https://doi.org/10.1038/s41408-021-00428-0
  14. Palladini G, Schönland SO, Sanchorawala V, Kumar S, Wechalekar A, Hegenbart U, et al. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid. 2021 Mar;28(1):1–2. doi: https://doi.org/10.1080/13506129.2020.1868810
  15. Muchtar E, Dispenzieri A, Wisniowski B, Palladini G, Milani P, Merlini G, et al. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. J Clin Oncol. 2023 Mar;41(7):1393–403. doi: https://doi.org/10.1200/JCO.22.00643
  16. Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017 Aug;130(5):625–31. doi: https://doi.org/10.1182/blood-2017-02-767467
  17. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al.; ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021 Jul;385(1):46–58. doi: https://doi.org/10.1056/NEJMoa2028631
  18. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al.; Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007 Sep;357(11):1083–93. doi: https://doi.org/10.1056/NEJMoa070484
  19. Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol. 2022 Jun;97(6):818–29. doi: https://doi.org/10.1002/ajh.26569
  20. Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC. Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica. 2011 Dec;96(12):1890–2. doi: https://doi.org/10.3324/haematol.2011.049858
  21. Basset M, Milani P, Nuvolone M, Benigna F, Rodigari L, Foli A, et al. Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. Blood Adv. 2020 Sep;4(17):4175–9. doi: https://doi.org/10.1182/bloodadvances.2020002219
  22. Nguyen VP, Landau H, Quillen K, Brauneis D, Shelton AC, Mendelson L, et al. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Biol Blood Marrow Transplant. 2018 Sep;24(9):1823–7. doi: https://doi.org/10.1016/j.bbmt.2018.06.018
  23. Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, et al. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant. 2007 Sep;40(6):557–62. doi: https://doi.org/10.1038/sj.bmt.1705746
  24. Manwani R, Hegenbart U, Mahmood S, Sachchithanantham S, Kyriakou C, Yong K, et al. Deferred autologous stem cell transplantation in systemic AL amyloidosis. Blood Cancer J. 2018 Nov;8(11):101. doi: https://doi.org/10.1038/s41408-018-0137-9
  25. Oubari S, Hegenbart U, Schoder R, Steinhardt M, Papathanasiou M, Rassaf T, et al. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival. Haematologica. 2024 Jan;109(1):220–30.
  26. Wechalekar AD, Sanchorawala V. Daratumumab in AL amyloidosis. Blood. 2022 Dec;140(22):2317–22. doi: https://doi.org/10.1182/blood.2021014613
  27. Palladini G, Foli A, Russo P, Milani P, Obici L, Lavatelli F, et al. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):143–5. doi: https://doi.org/10.3816/CLML.2011.n.033
  28. Milani P, Schönland S, Merlini G, Kimmich C, Foli A, Dittrich T, et al. Treatment of AL amyloidosis with bendamustine: a study of 122 patients. Blood. 2018 Nov;132(18):1988–91. doi: https://doi.org/10.1182/blood-2018-04-845396
  29. Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, et al. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström’s Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. J Clin Oncol. 2022 Jan;40(1):52–62. doi: https://doi.org/10.1200/JCO.21.00838
  30. Manwani R, Sachchithanantham S, Mahmood S, Foard D, Sharpley F, Rezk T, et al. Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine. Blood. 2018 Aug;132(7):761–4. doi: https://doi.org/10.1182/blood-2018-04-846493
  31. Dima D, Mazzoni S, Anwer F, Khouri J, Samaras C, Valent J, et al. Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of Therapeutic Innovation. JCO Oncol Pract. 2023 May;19(5):265–75. doi: https://doi.org/10.1200/OP.22.00396
  32. Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, et al. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood. 2018 Feb;131(5):525–32. doi: https://doi.org/10.1182/blood-2017-04-780544
  33. Revision Art. 71 a/b KVV. Schweiz Arzteztg. 2017 Jan;98(4):122–5. doi: https://doi.org/10.4414/saez.2017.05084
  34. Theodorakakou F, Fotiou D, Spiliopoulou V, Roussou M, Malandrakis P, Ntanasis-Stathopoulos I, et al. Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy. Br J Haematol. 2023 Nov;203(3):411–5. doi: https://doi.org/10.1111/bjh.19042
  35. Shragai T, Gatt M, Lavie N, Vaxman I, Tadmor T, Rouvio O, et al. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review. Eur J Haematol. 2021 Feb;106(2):184–95. doi: https://doi.org/10.1111/ejh.13535
  36. Rieger MJ, Pabst T, Jeker B, Paul P, Bergamini F, Bühler MM, et al. Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression. Ann Hematol. 2024 Oct;103(10):4163–70. doi: https://doi.org/10.1007/s00277-024-05901-x
  37. Lebel E, Kastritis E, Palladini G, Milani P, Theodorakakou F, Aumann S, et al. Venetoclax in Relapse/Refractory AL Amyloidosis-A Multicenter International Retrospective Real-World Study. Cancers (Basel). 2023 Mar;15(6):1710. doi: https://doi.org/10.3390/cancers15061710
  38. Le Bras F, et al. Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis. J. Clin. Oncol. 2019;37_suppl.15.e19538. doi.org/10.1200/JCO.2019.37.15_suppl.e1953
  39. Bochtler T, Hegenbart U, Heiss C, Benner A, Moos M, Seckinger A, et al. Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). Blood. 2011 Apr;117(14):3809–15. doi: https://doi.org/10.1182/blood-2010-02-268987
  40. Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, et al. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood. 2016 Jul;128(4):594–602. doi: https://doi.org/10.1182/blood-2015-10-676361
  41. Warsame R, LaPlant B, Kumar SK, Laumann K, Perez Burbano G, Buadi FK, et al. Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer J. 2020 Jan;10(1):4. doi: https://doi.org/10.1038/s41408-019-0266-9
  42. Wechalekar AD, Cibeira MT, Gibbs SD, Jaccard A, Kumar S, Merlini G, et al. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 2023 Mar;30(1):3–17. doi: https://doi.org/10.1080/13506129.2022.2093635
  43. Milani P, Sharpley F, Schönland SO, Basset M, Mahmood S, Nuvolone M, et al. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. Amyloid. 2020 Dec;27(4):231–6. doi: https://doi.org/10.1080/13506129.2020.1767566
  44. Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016 Aug;128(8):1059–62. doi: https://doi.org/10.1182/blood-2016-04-710822
  45. Wechalekar AD, Gillmore JD, Bird J, Cavenagh J, Hawkins S, Kazmi M, et al.; BCSH Committee. Guidelines on the management of AL amyloidosis. Br J Haematol. 2015 Jan;168(2):186–206. doi: https://doi.org/10.1111/bjh.13155
  46. Palladini G, Milani P, Foli A, Obici L, Lavatelli F, Nuvolone M, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica. 2014 Apr;99(4):743–50. doi: https://doi.org/10.3324/haematol.2013.095463
  47. Gibbs SD, Gillmore JD, Sattianayagam PT, Offer M, Lachmann HJ, Hawkins PN, et al. In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment. Blood. 2009 Nov;114(22):745. doi: https://doi.org/10.1182/blood.V114.22.745.745
  48. Dispenzieri A, Kastritis E, Wechalekar AD, Schönland SO, Kim K, Sanchorawala V, et al. A randomized phase 3 study of ixazomib-dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis. Leukemia. 2022 Jan;36(1):225–35. doi: https://doi.org/10.1038/s41375-021-01317-y
  49. Sanchorawala V, Wechalekar AD, Kim K, Schönland SO, Landau HJ, Kwok F, et al. Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician’s choice. Am J Hematol. 2023 May;98(5):720–9. doi: https://doi.org/10.1002/ajh.26866
  50. Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D’Souza A. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer J. 2023 Nov;13(1):172. doi: https://doi.org/10.1038/s41408-023-00950-3
  51. Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, et al. Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series. Blood. 2024 Feb;143(8):734–7. doi: https://doi.org/10.1182/blood.2023022937
  52. Das S, Ailawadhi S, Sher T, Roy V, Fernandez A, Parrondo RD. Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety. Curr Oncol. 2023 Oct;30(11):9627–33. doi: https://doi.org/10.3390/curroncol30110697
  53. Oliver-Caldes A, Jiménez R, Español-Rego M, Cibeira MT, Ortiz-Maldonado V, Quintana LF, et al. First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. J Immunother Cancer. 2021 Dec;9(12):3783. doi: https://doi.org/10.1136/jitc-2021-003783
  54. Lebel E, Asherie N, Kfir-Erenfeld S, Grisariu S, Avni B, Elias S, et al. Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis. J Clin Oncol. 2024 Dec;JCO2402252. doi: https://doi.org/10.1200/JCO-24-02252
  55. Cohen AD, Landau H, Scott EC, Liedtke M, Kaufman JL, Rosenzweig M, et al. Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Blood. 2016 Dec;128(22):645. doi: https://doi.org/10.1182/blood.V128.22.645.645
  56. Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol. 2016 Apr;34(10):1097–103. doi: https://doi.org/10.1200/JCO.2015.63.6530
  57. Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, et al. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med. 2015 Sep;373(12):1106–14. doi: https://doi.org/10.1056/NEJMoa1504942
  58. Merlini G, Liedtke M, Landau HJ, Comenzo RL, Sanchorawala V, Weiss BM, et al. The PRONTO amyloidosis study: A randomized, double-blind, placebo-controlled, global, phase 2b study of NEOD001 in previously treated subjects with light chain amyloidosis and persistent cardiac dysfunction. J Clin Oncol. 2016 May;34(15) _suppl):TPS8073–8073. doi: https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS8073
  59. Gertz MA, Cohen AD, Comenzo RL, Kastritis E, Landau HJ, Libby EN, et al. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood. 2023 Oct;142(14):1208–18. doi: https://doi.org/10.1182/blood.2022019406
  60. Mahmood S, Sachchithanantham S, Bridoux F, Lane T, Rannigan L, Foard D, et al. Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years. Blood. 2013 Nov;122(21):3143. doi: https://doi.org/10.1182/blood.V122.21.3143.3143
  61. Tahara S, Kohyama M, Nakamitsu A, Sugiyama Y, Tazaki T, Taogoshi H, et al. Surgical strategies for localized colorectal amyloidosis. Surg Case Rep. 2023 Apr;9(1):66. doi: https://doi.org/10.1186/s40792-023-01649-0
  62. Kennedy TL, Patel NM. Surgical management of localized amyloidosis. Laryngoscope. 2000 Jun;110(6):918–23. doi: https://doi.org/10.1097/00005537-200006000-00005
  63. Hall J, Rubinstein S, Lilly A, Blumberg JM, Chera B. Treatment of Localized Amyloid Light Chain Amyloidosis With External Beam Radiation Therapy. Pract Radiat Oncol. 2022;12(6):504–10. doi: https://doi.org/10.1016/j.prro.2022.03.011
  64. Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJ, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018 Dec;25(4):215–9. doi: https://doi.org/10.1080/13506129.2018.1549825
  65. Gertz MA, Lacy MQ, Dispenzieri A. Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev. 2004 Mar;18(1):17–37. doi: https://doi.org/10.1016/S0268-960X(03)00027-4
  66. Maroun BZ, Allam S, Chaulagain CP. Multidisciplinary supportive care in systemic light chain amyloidosis. Blood Res. 2022 Jun;57(2):106–16. doi: https://doi.org/10.5045/br.2022.2021227
  67. Wong SW, Fogaren T. Supportive Care for Patients with Systemic Light Chain Amyloidosis. Hematology/Oncology Clinics of North America. 2020;34(6:1177–1191. doi: https://doi.org/10.1016/j.hoc.2020.08.007
  68. Jensen CE, Byku M, Hladik GA, Jain K, Traub RE, Tuchman SA. Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis. Front Oncol. 2022;12:907584. doi: https://doi.org/10.3389/fonc.2022.907584
  69. Cheshire WP et al. Electrodiagnostic assessment of the autonomic nervous system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology. Clinical Neurophysiology. 2021;132(2):666–682. doi: https://doi.org/10.1016/j.clinph.2020.11.024
  70. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008 Jul;131(Pt 7):1912–25. doi: https://doi.org/10.1093/brain/awn093
  71. Cibeira MT, Ortiz-Pérez JT, Quintana LF, Fernádez De Larrea C, Tovar N, Bladé J. Supportive care in AL amyloidosis. Acta Haematologica. 2020;143(4):335–342. doi: https://doi.org/10.1159/000506760
  72. Shen KN, Fu WJ, Wu Y, Dong YJ, Huang ZX, Wei YQ, et al. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial. Circulation. 2022 Jan;145(1):8–17. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.055953
  73. Hora M, Carballo-Pacheco M, Weber B, Morris VK, Wittkopf A, Buchner J, et al. Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains. Sci Rep. 2017 Jan;7(1):41515. doi: https://doi.org/10.1038/srep41515
  74. Fernandes L, Cardim-Pires TR, Foguel D, Palhano FL. Green Tea Polyphenol Epigallocatechin-Gallate in Amyloid Aggregation and Neurodegenerative Diseases. Frontiers in Neuroscience. 2021;15. doi: https://doi.org/10.3389/fnins.2021.718188
  75. Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nature Reviews Cardiology. 2015;12(2):91–102. doi: https://doi.org/10.1038/nrcardio.2014.165
  76. Shams P, Ahmed I. Cardiac Amyloidosis. StatPearls Publishing; 2024.
  77. Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol. 1985 Jun;55(13 Pt 1):1645. doi: https://doi.org/10.1016/0002-9149(85)90995-6
  78. Dubrey SW, Burke MM, Khaghani A, Hawkins PN, Yacoub MH, Banner NR. Long term results of heart transplantation in patients with amyloid heart disease. Heart. 2001 Feb;85(2):202–7. doi: https://doi.org/10.1136/heart.85.2.202
  79. Kumar S, Li D, Joseph D, Trachtenberg B. State-of-the-art review on management of end-stage heart failure in amyloidosis: transplant and beyond. Heart Fail Rev. 2022;27(5):1567–1578. doi: https://doi.org/10.1007/s10741-021-10209-3
  80. Ashraf I, Peck MM, Maram R, Mohamed A, Ochoa Crespo D, Kaur G, et al. Association of Arrhythmias in Cardiac Amyloidosis and Cardiac Sarcoidosis. Cureus. 2020 Aug;12(8):e9842. doi: https://doi.org/10.7759/cureus.9842
  81. Weber N, et al. Management of systemic AL amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J. 2015;45(4):371–382. doi: https://doi.org/10.1111/imj.12566
  82. Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007 Nov;116(21):2420–6. doi: https://doi.org/10.1161/CIRCULATIONAHA.107.697763
  83. Palladini G, Malamani G, Cò F, Pistorio A, Recusani F, Anesi E, et al. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol. 2001 Aug;24(8 Pt 1):1228–33. doi: https://doi.org/10.1046/j.1460-9592.2001.01228.x
  84. Dhoble A, Khasnis A, Olomu A, Thakur R. Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review. Clin Cardiol. 2009 Aug;32(8):E63–5. doi: https://doi.org/10.1002/clc.20389
  85. Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack FU, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008 Feb;5(2):235–40. doi: https://doi.org/10.1016/j.hrthm.2007.10.016
  86. Varr BC, Zarafshar S, Coakley T, Liedtke M, Lafayette RA, Arai S, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm. 2014 Jan;11(1):158–62. doi: https://doi.org/10.1016/j.hrthm.2013.10.026
  87. ZeppenfeldK, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997–4126. doi: https://doi.org/10.1093/eurheartj/ehac262
  88. Mayr M, Dickenmann MJ. [Further evidence for the renoprotective effect of ACE inhibitors: ramipril protects against the progression of chronic renal insufficiency in non-diabetic nephropathy with nephrotic proteinuria]. Schweiz Med Wochenschr. 2000 Apr 1;130(13):491. doi:https://pubmed.ncbi.nlm.nih.gov/10812646/
  89. Paydas S. Report on 59 patients with renal amyloidosis. Int Urol Nephrol. 1999;31(5):619–31. doi: https://doi.org/10.1023/A:1007152320216
  90. Gentile G, Remuzzi G, Ruggenenti P. Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny. Nephron J. 2015;129(1):39–41. doi: https://doi.org/10.1159/000368331
  91. Gertz MA, Kyle RA, O’Fallon WM. Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients. Arch Intern Med. 1992 Nov;152(11):2245–50. doi: https://doi.org/10.1001/archinte.1992.00400230061010
  92. Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, et al. Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol. 2011 Feb;29(6):674–81. doi: https://doi.org/10.1200/JCO.2010.30.5235
  93. Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, Kumar S, et al. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant. 2011 Jun;26(6):2032–6. doi: https://doi.org/10.1093/ndt/gfr067
  94. Angel-Korman A, Stern L, Sarosiek S, Sloan JM, Doros G, Sanchorawala V, et al. Long-term outcome of kidney transplantation in AL amyloidosis. Kidney Int. 2019 Feb;95(2):405–11. doi: https://doi.org/10.1016/j.kint.2018.09.021
  95. Kunin M, Klempfner R, Beckerman P, Rott D, Dinour D. Congestive heart failure treated with peritoneal dialysis or hemodialysis: typical patient profile and outcomes in real-world setting. Int J Clin Pract. 2021 Mar;75(3):e13727. doi: https://doi.org/10.1111/ijcp.13727
  96. Sattianayagam PT, Gibbs SD, Pinney JH, Wechalekar AD, Lachmann HJ, Whelan CJ, et al. Solid organ transplantation in AL amyloidosis. Am J Transplant. 2010 Sep;10(9):2124–31. doi: https://doi.org/10.1111/j.1600-6143.2010.03227.x
  97. Fritz CD, Blaney E. Evaluation and Management Strategies for GI Involvement with Amyloidosis. Am J Med. 2022 Apr;135 Suppl 1:S20–3. doi: https://doi.org/10.1016/j.amjmed.2022.01.008
  98. Mumford AD, O’Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol. 2000 Aug;110(2):454–60. doi: https://doi.org/10.1046/j.1365-2141.2000.02183.x
  99. Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018 Oct;4(1):38. 10.1038/s41572-018-0034-3
  100. Cruz DN. Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension. Expert Opin Pharmacother. 2000 May;1(4):835–40. doi: https://doi.org/10.1517/14656566.1.4.835
  101. Bundesamt für Gesundheit (BAG). Spezialitätenliste (SL) - Präparate. Available from: https://spezialitaetenliste.ch/ShowPreparations.aspx?searchType=SUBSTANCE